Diabetes Mellitus, Type 2 Clinical Trial
— PYHOfficial title:
The Effects of an 8-week Vegan Diet on Trimethylamine-N-Oxide (TMAO) Levels and Post-challenge Glucose Levels in Individuals With Dysglycaemia (The Plant Your Health Study)
NCT number | NCT03315988 |
Other study ID # | 0625 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 4, 2017 |
Est. completion date | January 7, 2019 |
Verified date | September 2018 |
Source | University of Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The amount of people with diabetes mellitus has now reached over 4 million in the United
Kingdom. Type 2 diabetes accounts for the majority of all cases of diabetes and increases the
risk of many other diseases such as heart problems. Plant based diets are thought to be an
effective way to improve markers of health related to type 2 diabetes and heart disease. One
way that a plant based diet improves health could be through reducing waste products that are
generated in the gut by the bacteria that break down food as part of the digestion process.
For example, the digestion of some meats, fish and eggs results in the creation of a
substance called Trimethylamine-N-Oxide (TMAO) which has been linked to worse health outcomes
in several studies. However, the full impact on TMAO and blood glucose levels of swapping
regular meat consumption for a plant based vegan diet is not fully understood and requires
further research. Therefore, the aim of this study will be to develop and undertake a
clinical trial to investigate the effects of an 8-week vegan diet on TMAO levels and post
challenge glucose levels in individuals with dysglycaemia (drug naïve).
The study will be interventional single group prospective trial of adults aged 18-75 years of
age from a multi-ethnic population with dysglycaemia (drug naïve). A sample of 29 people will
be sought. The dietary intervention (vegan diet) will last 8 weeks. Then, the participants
will go back to their normal diet and come for their final visit after a four week follow-up
period (week 12). To assess the effectiveness of the intervention, primary and secondary
outcome data collected at baseline will be compared with data collected at 1 week, 8 weeks
and 12 weeks.
Status | Completed |
Enrollment | 28 |
Est. completion date | January 7, 2019 |
Est. primary completion date | January 7, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study - And either: - Overweight (White: BMI>25 - <30, South Asian/ Black and minority ethnic group <27.5) with HbA1c between HbA1c =5.7% and = 8% (39-64 mmol/mol) identified within the last 36 months - Obese: (White: BMI =30, South Asian/ Black and minority ethnic group: =27.5) - Male or Female - Aged 18 - 75 years inclusive - Able to understand, read and speak the English language to a sufficient level to understand and take part to the study in the investigators opinion - Have access to a phone, and willing to use it as part of the study - Regular meat and/or fish eater (at least 3 times per week)-self reported Exclusion Criteria: Participant is unwilling or unable to give informed consent - Non-English speakers - HbA1c above 8% (64 mmol/mol) - Taking any form of glucose lowering medication currently or within the last 60 days - Current smokers - Current use of vegan or vegetarian diet - Recent significant weight change (10% or more) over the last 3 months - Pregnancy/lactation - Clinical eating disorder as detected by their GP or relevant health professional (e.g. dietitian) - Have a terminal illness - Current or recent (within 6 months) oral antibiotics or steroid use as their usage could impact on the gut bacteria profile - Ongoing CVD (e.g. angina) * - In the circumstance that an individual is not sure whether they meet the inclusion/ exclusion criteria, (i.e. they are not sure if they have ongoing CVD) this will be reviewed by a named medic on the delegation of authority log for a clinical decision to be made during baseline. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leicester Diabetes Centre | Leicester |
Lead Sponsor | Collaborator |
---|---|
University of Leicester | University Hospitals, Leicester |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline TMAO plasma levels at 1, 8 and 12 weeks. | urine and plasma samples for TMAO (µM) | at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days) | |
Primary | Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks. | blood samples (mmol/l) | at 1 (+ 5 days) week , 8 (+/- 5 days) weeks and 12 weeks (+/- 5 days) | |
Secondary | TMAO (µM) urine levels at baseline. | urine samples | at baseline | |
Secondary | Change from Baseline in TMAO urine/plasma levels at 1 week following a vegan diet. | urine and plasma samples; TMAO (µM) | at 1 week (+ 5 days) | |
Secondary | Change from Baseline 3-hour post-challenge glucose levels at 1 week following a vegan diet. | blood samples for glucose (mmol/l) | at 1 week (+ 5 days) | |
Secondary | Change from week 8 in TMAO urine/plasma levels at 4 weeks after diet has returned to normal (week 12). | urine and plasma samples for TMAO (µM) | at 12 weeks (+/- 5 days) | |
Secondary | Change from week 8 in 3-hour post-challenge glucose levels at 4 weeks after diet has returned to normal (week 12). | blood samples for glucose (mmol/l) | at 12 weeks (+/- 5 days) | |
Secondary | Change from Baseline in body composition using dual energy X-ray absorptiometry (DXA) scan at 8 weeks following a vegan diet. | DXA Scan | at baseline and week 8 (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 1 week. | blood samples (mmol/l) | 1 week (+5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 8 weeks. | blood samples (mmol/l) | 8 weeks (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including post-challenge insulin at 12 weeks. | blood samples (mmol/l) | 12 weeks (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and at 1 week. | blood samples (mmol/l) | 1 week (+5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids and inflammatory markers at 8 weeks. | blood samples (mmol/l) | 8 weeks (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including fasting lipids at 12 weeks. | blood samples (mmol/l) | 12 weeks (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 1 week. | blood samples (mmol/l) | 1 week (+5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 8 weeks. | blood samples (mmol/l) | 8 weeks (+/- 5 days) | |
Secondary | Change from Baseline in biochemical measures of cardiometabolic health including inflammatory markers at 12 weeks. | blood samples (mmol/l) | 12 weeks (+/- 5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to body composition. | DXA scan | baseline | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to body composition. | DXA scan | week 8 (+/- 5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | 3-day diet diaries | baseline | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | 3-day diet diaries | counselling visit (+5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | 3-day diet diaries | week 1 (+5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | 3-day diet diaries | week 8 (+/- 5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | 3-day diet diaries | week 12 (+/- 5 days) | |
Secondary | The extent to which changes in the primary outcomes are mediated by, or independent of, changes to lifestyle factors. | accelerometers | weeks 1-12 | |
Secondary | Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet. | semi-structured interviews | at week 12 (+/- 5 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |